Comparison of Enoxaparin and Warfarin for Secondary Prevention of Cancer-Associated Stroke

Table 2

Summary of detailed characteristics of subjects with recurrent stroke.

Number	Sex	Age	Treatment	D-dimer level; (μg/mL) on admission	D-dimer level; (μg/mL) at the time of recurrence	INR at the time of recurrence	Time to recurrence (months)	Primary cancer type	Adenocarcinoma	Systemic metastasis
1	Female	55	Warfarin	19.54	47.80	3.04	1.13	Lung	Yes	Yes
2	Male	72	Warfarin	1.91	2.96	1.48	0.80	Lung	Yes	No
3	Female	59	Warfarin	72.40	47.20	2.60	0.83	CBD	Yes	Yes
4	Male	61	Warfarin	60.00	39.72	2.62	0.46	Colon	Yes	Yes
5	Female	60	Warfarin	18.36	10.30	1.39	8.30	Lung	Yes	Yes
6	Female	51	Warfarin	11.74	57.93	5.51	19.63	Lung	Yes	Yes
7	Female	48	Warfarin	4.83	0.34	3.26	1.90	Lung	Yes	Yes
8	Female	75	Warfarin	14.87	14.74	2.06	0.37	Pancreas	Yes	Yes
9	Male	67	Enoxaparin	60.00	60.00	N/A^†	0.43	CBD^‡	Yes	Yes

INR, international normalized ratio; ^†N/A: not applicable; ^‡CBD: common bile duct.